Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares fell to a low of $70.0601 before closing at $71.42. Intraday shares traded counted 0.73 million, which was 3.95% higher than its 30-day average trading volume of 759.58K. ARWR’s previous close was $72.26 while the outstanding shares total 103.87M. The firm has a beta of 1.30. The stock’s Relative Strength Index (RSI) is 54.05, with weekly volatility at 5.50% and ATR at 3.51. The ARWR stock’s 52-week price range has touched low of $30.83 and a $92.60 high. The stock traded lower over the last trading session, losing -1.16% on 05/19/21.
Investors have identified the Biotechnology company Arrowhead Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $6.93 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Arrowhead Pharmaceuticals Inc. (ARWR) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 586.76 million total, with 167.19 million as their total liabilities.
ARWR were able to record 213.51 million as free cash flow during the 08/10/2021 quarter of the year, this saw their quarterly net cash flow reduce by 228.79 million. In cash movements, the company had a total of 224.95 million as operating cash flow.
Potential earnings growth for Arrowhead Pharmaceuticals Inc. (ARWR)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/10/2021 quarter of the year, Arrowhead Pharmaceuticals Inc. recorded a total of 32.81 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 28.29% coming in sequential stages and their sales for the 08/10/2021 quarter increasing by 35.07%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 32.81 million trying to sell their products during the last quarter, with the result yielding a gross income of 61.04 million. This allows shareholders to hold on to 103.87M with the recently reported earning now reading -0.26 cents per share. This is a figure that compared to analyst’s prediction for their 08/10/2021 (-0.26 cents a share).
Having a look at the company’s valuation, the company is expected to record -0.13 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ARWR sounds very interesting.
Is the stock of ARWR attractive?
In related news, Director, GIVEN DOUGLAS B sold 1,125 shares of the company’s stock in a transaction that recorded on Feb 22. The sale was performed at an average price of 88.73, for a total value of 99,821. As the sale deal closes, the General Counsel, O’Brien Patrick now sold 90,000 shares of the company’s stock, valued at 7,961,240. Also, Director, GIVEN DOUGLAS B sold 3,000 shares of the company’s stock in a deal that was recorded on Jan 15. The shares were price at an average price of 83.28 per share, with a total market value of 249,840. Following this completion of acquisition, the Senior Vice President, Hamilton James C now holds 10,000 shares of the company’s stock, valued at 812,942. In the last 6 months, insiders have changed their ownership in shares of company stock by 4.60%.
9 out of 11 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Arrowhead Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the ARWR stock. The 12-month mean consensus price target for the company’s shares has been set at $91.17.